We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Novel Capsule-Based Smell Test Could Help Diagnose COVID-19 in Broader Population

By LabMedica International staff writers
Posted on 29 Apr 2021
A new smell test has been found to be easy to use in patients with Parkinson’s disease, and could also be helpful in diagnosing COVID-19 in the broader population.

The novel smell testing kit developed by researchers at Queen Mary University of London (London, UK) uses capsules of aromatic oils placed between two strips of single-sided tape. More...
To take the smell test, the capsules are simply crushed between the fingers and the tape strip peeled to release the aroma contained within the capsules. Based on a person’s ability to recognize these smells, a score would be generated that can be sent to their GP if they are experiencing a loss of smell.

In their study, the researchers showed that in a small group of eight patients with Parkinson’s disease, the smells from the tests were detectable. The participants also cited the relative ease process of rupturing the capsules, particularly for those with tremors, compared to the standard scratch and sniff smell test available on the market.

“Our capsule-based smell test can assist in the rapid diagnostic of various diseases linked to the loss of smell. These include chronic neurological conditions such as Parkinson’s and Alzheimer’s disease, as well as COVID-19, which is known to affect the sense of smell,” said lead researcher Dr. Ahmed Ismail from Queen Mary’s School of Engineering and Materials Science. “Being non-invasive and less stressful, the capsule-based smell test has benefits over the nose swab in diagnosing COVID-19.”

Dr. Ismail added: “Most of the smell tests on the market depend on using paperboard items treated with a fragrant coating called scratch and sniff, in which you need to scratch a card to release the odor. The problem with this approach is that the amount of odor released depends on the extent to which the individual scratches, something that might affect the outcome of the test.

“Our capsule-based smell test doesn’t have this problem because the amount of odor released is controlled by the amount of oil precisely encapsulated. The mass-production of our new test would also be cheaper than a scratch and sniff test.”

Related Links:
Queen Mary University of London


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
SARS-CoV-2 PCR Test
Macurra SARS-CoV-2 PCR Kit
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.